logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table PPP-5. Potency of cannabis products at retail level, 2005 [see all tables in this series...]

Part (iii) Sampling frame/type of study

CountrySampling frame/type of study
BelgiumSmall seizures (mostly at user's level)/judicial cases analysed in the framework of the project 'Composition of drugs in circulation'.
BulgariaAll seizures/routine analysis of seizures.
Czech RepublicAll seizures (analysed in Prague and 3 out of 7 regional police laboratories)/routine analysis of seizures.
GermanyAll seizures/routine analysis of seizures.
EstoniaAll seizures which weight more than 9 g./routine analysis of seizures.
France-AAll seizures/routine analysis of seizures.
France-BUser's level: local sampling/ad hoc study.
LuxembourgAll seizures/routine analysis of seizures.
HungaryAll seizures submitted for analysis of over 5 g. for cannabis resin/routine analysis of seizures.
MaltaAll seizures/routine analysis of seizures.
The NetherlandsUser's level: random test purchases in coffee shops/monitoring system.
AustriaAll seizures/routine analysis of seizures.
PolandNot all seizures (but includes material from cannabis cultivations)/routine analysis of seizures.
PortugalAll seizures/routine analysis of seizures.
SlovakiaAll seizures/routine analysis of seizures.
UK (England and Wales)All seizures, purchases/routine analysis of seizures.

Page last updated: Tuesday, 13 November 2007